TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

April 30, 1995

Study Completion Date

March 31, 2001

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

Rifapentine

DRUG

Isoniazid

Trial Locations (23)

10016

New York University School of Medicine, New York

10032

Columbia University/Presbyterian Medical Center, New York

10037

Harlem Hospital Center, New York

20422

Washington, D.C. VAMC, Washington D.C.

28203

Carolinas Medical Center, Charlotte

34222

Duke University Medical Center, Durham

60141

Hines VA Medical Center, Hines

60611

Chicago VA Medical Center (Lakeside), Chicago

72205

Central Arkansas Veterans Health System, Little Rock

77009

Thomas Street Clinic, Houston

78284

Audi L. Murphy VA Hospital, San Antonio

80204

Denver Department of Public Health and Hospitals, Denver

90033

LA County/USC Medical Center, Los Angeles

94110

University of California, San Francisco, San Francisco

98104

Seattle King County Health Department, Seattle

21287-0003

Johns Hopkins University School of Medicine, Baltimore

02118

Boston Medical Center, Boston

07107-3001

New Jersey Medical School, Newark

37212-2637

Nashville VA Medical Center, Nashville

76107-2699

University of North Texas Health Science Center, Fort Worth

Canada V5Z 4R4

University of British Columbia, Vancouver

CANADA R3A 1R8

University of Manitoba, Winnipeg

H2X 2P4Pq Canada

Montreal Chest Institute McGill University, Montreal

All Listed Sponsors
collaborator

US Department of Veterans Affairs

FED

lead

Centers for Disease Control and Prevention

FED

NCT00023335 - TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis | Biotech Hunter | Biotech Hunter